Gliatilin, 400 mg capsules 56 pcs

Pharmacotherapeutic group: nootropic medicine

ATX code:

Pharmacological Properties

Pharmacodynamics

Gliatilin is choline alphoscerate, which is a cholinomimetic of central action with predominant effect on the central nervous system.

The drug contains 40.5 % of choline which is released from the compound in the brain; choline participates in the biosynthesis of acetylcholine (one of the main mediators of nerve excitation). Alphoscerate is biotransformed to glycerophosphate, which is a precursor of phospholipids.

Acetylcholine has a positive effect on nerve impulse transmission, and glycerophosphate participates in the synthesis of phosphatidylcholine (membrane phospholipid), as a result improving membrane elasticity and receptor function.

Gliatylin increases metabolic processes and activates the structures of the reticular formation of the brain.

It has a preventive and corrective effect on factors of involutional psychoorganic syndrome, such as changes in the phospholipid composition of neuronal membranes and decreased cholinergic activity.

Pharmacodynamic studies have shown that Gliatilin acts on synaptic, including cholinergic transmission of nerve impulse (neurotransmission), neuronal membrane plasticity and receptor function.

Pharmacokinetics

Absorption when ingested is 88%; easily penetrates the blood-brain barrier, accumulates mainly in the brain (concentration in the brain reaches 45% of blood levels), lungs and liver; 85% is excreted by the lungs as carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestine.

It does not affect the reproductive cycle, has no teratogenic and mutagenic effects.